{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T16:37:57Z","timestamp":1784565477913,"version":"3.55.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2020,6,8]],"date-time":"2020-06-08T00:00:00Z","timestamp":1591574400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,6,8]],"date-time":"2020-06-08T00:00:00Z","timestamp":1591574400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Herz"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1007\/s00059-020-04951-x","type":"journal-article","created":{"date-parts":[[2020,6,8]],"date-time":"2020-06-08T16:06:12Z","timestamp":1591632372000},"page":"619-625","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Oncocardiology: new challenges, new opportunities","Onkokardiologie: Neue Herausforderungen, neue M\u00f6glichkeiten"],"prefix":"10.1007","volume":"45","author":[{"given":"Lars","family":"Michel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Schadendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tienush","family":"Rassaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,8]]},"reference":[{"key":"4951_CR1","unstructured":"Destatis (2017) Todesursachen in Deutschland. https:\/\/www.destatis.de\/DE\/Themen\/Gesellschaft-Umwelt\/Gesundheit\/Todesursachen\/Publikationen\/Downloads-Todesursachen\/todesursachen-2120400157004.pdf?__blob=publicationFile. Accessed 1 May 2020"},{"key":"4951_CR2","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ijcard.2019.01.038","volume":"280","author":"M Totzeck","year":"2019","unstructured":"Totzeck\u00a0M, Schuler\u00a0M, Stuschke\u00a0M et al (2019) Cardio-oncology\u2014strategies for management of cancer-therapy related cardiovascular disease. Int J Cardiol 280:163\u2013175","journal-title":"Int J Cardiol"},{"issue":"7","key":"4951_CR3","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1161\/CIRCULATIONAHA.117.030816","volume":"138","author":"C Meijers Wouter","year":"2018","unstructured":"Meijers Wouter\u00a0C, Maglione\u00a0M, Bakker Stephan\u00a0JL et\u00a0al (2018) Heart failure stimulates tumor growth by circulating factors. Circulation 138(7):678\u2013691","journal-title":"Circulation"},{"issue":"36","key":"4951_CR4","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","volume":"37","author":"JL Zamorano","year":"2016","unstructured":"Zamorano\u00a0JL, Lancellotti\u00a0P, Rodriguez Mu\u00f1oz\u00a0D et\u00a0al (2016) 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC committee for practice guidelines: the task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart\u00a0J 37(36):2768\u20132801","journal-title":"Eur Heart J"},{"key":"4951_CR5","unstructured":"Rassaf T, Lehmann L (2020) Cardio-oncology in Germany. https:\/\/www.escardio.org\/Councils\/council-of-cardio-oncology\/cardio-oncology-in-germany. Accessed 1 May 2020"},{"key":"4951_CR6","first-page":"12","volume":"5","author":"J Peng","year":"2019","unstructured":"Peng\u00a0J, Rushton\u00a0M, Johnson\u00a0C et\u00a0al (2019) An international survey of healthcare providers\u2019 knowledge of cardiac complications of cancer treatments. Cardiooncology 5:12","journal-title":"Cardiooncology"},{"issue":"Suppl 35","key":"4951_CR7","doi-asserted-by":"crossref","first-page":"S4282","DOI":"10.21037\/jtd.2018.08.15","volume":"10","author":"L Michel","year":"2018","unstructured":"Michel\u00a0L, Rassaf\u00a0T, Totzeck\u00a0M (2018) Biomarkers for the detection of apparent and subclinical cancer therapy-related cardiotoxicity. J\u00a0Thorac Dis 10(Suppl 35):S4282\u2013S4295","journal-title":"J Thorac Dis"},{"issue":"1","key":"4951_CR8","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s10557-016-6711-0","volume":"31","author":"JV McGowan","year":"2017","unstructured":"McGowan\u00a0JV, Chung\u00a0R, Maulik\u00a0A et\u00a0al (2017) Anthracycline chemotherapy and cardiotoxicity. Cardiovasc Drugs Ther 31(1):63\u201375","journal-title":"Cardiovasc Drugs Ther"},{"issue":"2","key":"4951_CR9","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/ejhf.1631","volume":"22","author":"L Michel","year":"2020","unstructured":"Michel\u00a0L, Mincu\u00a0RI, Mahabadi\u00a0AA et al (2020) Troponins and brain natriuretic peptides for the prediction of cardiotoxicity in cancer patients: a\u00a0meta-analysis. Eur J Heart Fail 22(2):350\u2013361","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"4951_CR10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40001-018-0359-0","volume":"24","author":"L Michel","year":"2019","unstructured":"Michel\u00a0L, Rassaf\u00a0T (2019) Cardio-oncology: need for novel structures. Eur J Med Res 24(1):1","journal-title":"Eur J Med Res"},{"key":"4951_CR11","first-page":"100420","volume":"25","author":"L Michel","year":"2019","unstructured":"Michel\u00a0L, Rassaf\u00a0T, Totzeck\u00a0M (2019) Cardiotoxicity from immune checkpoint inhibitors. Int J Cardiol Heart Vasc 25:100420","journal-title":"Int J Cardiol Heart Vasc"},{"issue":"9","key":"4951_CR12","doi-asserted-by":"crossref","first-page":"e447","DOI":"10.1016\/S1470-2045(18)30457-1","volume":"19","author":"AR Lyon","year":"2018","unstructured":"Lyon\u00a0AR, Yousaf\u00a0N, Battisti\u00a0NML et\u00a0al (2018) Immune checkpoint inhibitors and cardiovascular toxicity. Lancet Oncol 19(9):e447\u2013e458","journal-title":"Lancet Oncol"},{"issue":"8","key":"4951_CR13","doi-asserted-by":"crossref","first-page":"e006278","DOI":"10.1161\/JAHA.117.006278","volume":"6","author":"M Totzeck","year":"2017","unstructured":"Totzeck\u00a0M, Mincu Raluca\u00a0I, Rassaf\u00a0T (2017) Cardiovascular adverse events in patients with cancer treated with bevacizumab: a meta-analysis of more than 20 000 patients. J\u00a0Am Heart Assoc 6(8):e6278","journal-title":"J Am Heart Assoc"},{"issue":"6","key":"4951_CR14","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.semnephrol.2010.09.007","volume":"30","author":"ES Robinson","year":"2010","unstructured":"Robinson\u00a0ES, Khankin\u00a0EV, Karumanchi\u00a0SA, Humphreys\u00a0BD (2010) Hypertension induced by vascular endothelial growth factor signaling pathway inhibition: mechanisms and potential use as a\u00a0biomarker. Semin Nephrol 30(6):591\u2013601","journal-title":"Semin Nephrol"},{"issue":"8","key":"4951_CR15","doi-asserted-by":"crossref","first-page":"e198890","DOI":"10.1001\/jamanetworkopen.2019.8890","volume":"2","author":"RI Mincu","year":"2019","unstructured":"Mincu\u00a0RI, Mahabadi\u00a0AA, Michel\u00a0L et al (2019) Cardiovascular adverse events associated with BRAF and MEK inhibitors: a systematic review and meta-analysis. JAMA Netw Open 2(8):e198890","journal-title":"JAMA Netw Open"},{"issue":"20","key":"4951_CR16","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1056\/NEJMoa1406037","volume":"371","author":"GV Long","year":"2014","unstructured":"Long\u00a0GV, Stroyakovskiy\u00a0D, Gogas\u00a0H et\u00a0al (2014) Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N\u00a0Engl J Med 371(20):1877\u20131888","journal-title":"N Engl J Med"},{"issue":"6","key":"4951_CR17","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1038\/s41591-019-0476-5","volume":"25","author":"A Ribas","year":"2019","unstructured":"Ribas\u00a0A, Lawrence\u00a0D, Atkinson\u00a0V et al (2019) Combined BRAF and MEK inhibition with PD\u20111 blockade immunotherapy in BRAF-mutant melanoma. Nat Med 25(6):936\u2013940","journal-title":"Nat Med"},{"issue":"3","key":"4951_CR18","doi-asserted-by":"crossref","first-page":"e174519","DOI":"10.1001\/jamaoncol.2017.4519","volume":"4","author":"AJ Waxman","year":"2018","unstructured":"Waxman\u00a0AJ, Clasen\u00a0S, Hwang\u00a0WT et al (2018) Carfilzomib-associated cardiovascular adverse events: a systematic review and meta-analysis. JAMA Oncol 4(3):e174519","journal-title":"JAMA Oncol"},{"issue":"12","key":"4951_CR19","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/s41408-017-0026-7","volume":"7","author":"T Jain","year":"2017","unstructured":"Jain\u00a0T, Narayanasamy\u00a0H, Mikhael\u00a0J et\u00a0al (2017) Systolic dysfunction associated with carfilzomib use in patients with multiple myeloma. Blood Cancer\u00a0J 7(12):642","journal-title":"Blood Cancer J"},{"issue":"11","key":"4951_CR20","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1080\/10428194.2018.1437269","volume":"59","author":"C Shah","year":"2018","unstructured":"Shah\u00a0C, Bishnoi\u00a0R, Jain\u00a0A et al (2018) Cardiotoxicity associated with carfilzomib: systematic review and meta-analysis. Leuk Lymphoma 59(11):2557\u20132569","journal-title":"Leuk Lymphoma"},{"key":"4951_CR21","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1186\/1471-2407-14-915","volume":"14","author":"A Chari","year":"2014","unstructured":"Chari\u00a0A, Hajje\u00a0D (2014) Case series discussion of cardiac and vascular events following carfilzomib treatment: possible mechanism, screening, and monitoring. BMC Cancer 14:915","journal-title":"BMC Cancer"},{"issue":"7","key":"4951_CR22","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1182\/blood-2018-06-858415","volume":"133","author":"P Efentakis","year":"2019","unstructured":"Efentakis\u00a0P, Kremastiotis\u00a0G, Varela\u00a0A et al (2019) Molecular mechanisms of carfilzomib-induced cardiotoxicity in mice and the emerging cardioprotective role of metformin. Blood 133(7):710\u2013723","journal-title":"Blood"},{"issue":"22","key":"4951_CR23","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1182\/blood.2019000840","volume":"134","author":"T Dickerson","year":"2019","unstructured":"Dickerson\u00a0T, Wiczer\u00a0T, Waller\u00a0A et\u00a0al (2019) Hypertension and incident cardiovascular events following ibrutinib initiation. Blood 134(22):1919\u20131928","journal-title":"Blood"},{"issue":"5","key":"4951_CR24","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1056\/NEJMoa1817073","volume":"381","author":"TD Shanafelt","year":"2019","unstructured":"Shanafelt\u00a0TD, Wang\u00a0XV, Kay\u00a0NE et al (2019) Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. N\u00a0Engl J Med 381(5):432\u2013443","journal-title":"N Engl J Med"},{"key":"4951_CR25","doi-asserted-by":"crossref","unstructured":"FDA (2020) FDA approves ibrutinib plus rituximab for chronic lymphocytic leukemia. https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-approves-ibrutinib-plus-rituximab-chronic-lymphocytic-leukemia. Accessed 1 May 2020","DOI":"10.1097\/01.COT.0000553964.13264.7a"},{"issue":"11","key":"4951_CR26","first-page":"970","volume":"30","author":"A Vrontikis","year":"2016","unstructured":"Vrontikis\u00a0A, Carey\u00a0J, Gilreath\u00a0JA et al (2016) Proposed algorithm for managing ibrutinib-related atrial fibrillation. Oncology 30(11):970\u2013981 (C3)","journal-title":"Oncology"},{"issue":"3","key":"4951_CR27","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/bjh.14324","volume":"175","author":"PA Thompson","year":"2016","unstructured":"Thompson\u00a0PA, L\u00e9vy\u00a0V, Tam\u00a0CS et\u00a0al (2016) Atrial fibrillation in CLL patients treated with ibrutinib. An international retrospective study. Br J Haematol 175(3):462\u2013466","journal-title":"Br J Haematol"},{"issue":"12","key":"4951_CR28","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.jacep.2018.06.004","volume":"4","author":"S Ganatra","year":"2018","unstructured":"Ganatra\u00a0S, Sharma\u00a0A, Shah\u00a0S et al (2018) Ibrutinib-associated atrial fibrillation. JACC Clin Electrophysiol 4(12):1491\u20131500","journal-title":"JACC Clin Electrophysiol"},{"issue":"1","key":"4951_CR29","doi-asserted-by":"crossref","first-page":"74","DOI":"10.2174\/1871529X19666190912150942","volume":"20","author":"MP Mahjoob","year":"2020","unstructured":"Mahjoob\u00a0MP, Sheikholeslami\u00a0SA, Dadras\u00a0M et al (2020) Prognostic value of cardiac biomarkers assessment in combination with myocardial 2D strain echocardiography for early detection of anthracycline-related cardiac toxicity. Cardiovasc Hematol Disord Drug Targets 20(1):74\u201383","journal-title":"Cardiovasc Hematol Disord Drug Targets"},{"issue":"3","key":"4951_CR30","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1002\/ejhf.8","volume":"16","author":"Y Kang","year":"2014","unstructured":"Kang\u00a0Y, Xu\u00a0X, Cheng\u00a0L, Li\u00a0L, Sun\u00a0M, Chen\u00a0H, Pan\u00a0C, Shu\u00a0X (2014) Two-dimensional speckle tracking echocardiography combined with high-sensitive cardiac troponin T in early detection and prediction of cardiotoxicity during epirubicine-based chemotherapy. Eur J Heart Fail 16(3):300\u2013308","journal-title":"Eur J Heart Fail"},{"key":"4951_CR31","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-020-09938-8","author":"K Keramida","year":"2020","unstructured":"Keramida\u00a0K, Farmakis\u00a0D (2020) Right ventricular involvement in cancer therapy-related cardiotoxicity: the emerging role of strain echocardiography. Heart Fail Rev. https:\/\/doi.org\/10.1007\/s10741-020-09938-8","journal-title":"Heart Fail Rev"},{"issue":"1","key":"4951_CR32","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jaccao.2020.01.007","volume":"2","author":"R Zhao","year":"2020","unstructured":"Zhao\u00a0R, Shu\u00a0F, Zhang\u00a0C et al (2020) Early detection and prediction of\u00a0anthracycline-induced right\u00a0ventricular cardiotoxicity by 3\u2011dimensional echocardiography. JACC CardioOncol 2(1):13\u201322","journal-title":"JACC CardioOncol"},{"key":"4951_CR33","doi-asserted-by":"publisher","DOI":"10.1007\/s12350-019-01617-y","author":"J Kim","year":"2019","unstructured":"Kim\u00a0J, Cho\u00a0SG, Kang\u00a0SR et al (2019) Association between FDG uptake in the right ventricular myocardium and cancer therapy-induced cardiotoxicity. J\u00a0Nucl Cardiol. https:\/\/doi.org\/10.1007\/s12350-019-01617-y","journal-title":"J Nucl Cardiol"},{"key":"4951_CR34","doi-asserted-by":"publisher","DOI":"10.1007\/s12350-018-01584-w","author":"HJ Verberne","year":"2019","unstructured":"Verberne\u00a0HJ, Verschure\u00a0DO (2019) Anthracycline-induced cardiotoxicity: Is there a\u00a0role for myocardial (123)I-mIBG scintigraphy? J\u00a0Nucl Cardiol. https:\/\/doi.org\/10.1007\/s12350-018-01584-w","journal-title":"J Nucl Cardiol"},{"issue":"5","key":"4951_CR35","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/s41569-020-0360-5","volume":"17","author":"YY Zheng","year":"2020","unstructured":"Zheng\u00a0YY, Ma\u00a0YT, Zhang\u00a0JY, Xie\u00a0X (2020) COVID-19 and the cardiovascular system. Nat Rev Cardiol 17(5):259\u2013260","journal-title":"Nat Rev Cardiol"},{"issue":"10234","key":"4951_CR36","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/S0140-6736(20)30937-5","volume":"395","author":"Z Varga","year":"2020","unstructured":"Varga\u00a0Z, Flammer\u00a0AJ, Steiger\u00a0P et al (2020) Endothelial cell infection and endotheliitis in COVID-19. Lancet 395(10234):1417\u20131418","journal-title":"Lancet"},{"issue":"1","key":"4951_CR37","doi-asserted-by":"crossref","first-page":"78","DOI":"10.5144\/0256-4947.2016.78","volume":"36","author":"T Alhogbani","year":"2016","unstructured":"Alhogbani\u00a0T (2016) Acute myocarditis associated with novel Middle East respiratory syndrome coronavirus. Ann Saudi Med 36(1):78\u201380","journal-title":"Ann Saudi Med"},{"key":"4951_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2020.03.001","author":"S Ganatra","year":"2020","unstructured":"Ganatra\u00a0S, Hammond\u00a0SP, Nohria\u00a0A (2020) The novel coronavirus disease (COVID-19) threat for patients with cardiovascular disease and cancer. JACC CardioOncol. https:\/\/doi.org\/10.1016\/j.jaccao.2020.03.001","journal-title":"JACC CardioOncol"},{"key":"4951_CR39","unstructured":"CardioSmart (2020) Coronavirus and your heart. https:\/\/www.cardiosmart.org\/~\/media\/Images\/Infographics\/Coronavirus-and-Your-Heart-Dont-Ignore-Heart-Symptoms.ashx. Accessed 1 May 2020"},{"key":"4951_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2020.04.003","author":"A Parikh","year":"2020","unstructured":"Parikh\u00a0A, Kumar\u00a0AA, Jahangir\u00a0E (2020) Cardio-oncology care in the time of COVID-19 and the role of telehealth. JACC CardioOncol. https:\/\/doi.org\/10.1016\/j.jaccao.2020.04.003","journal-title":"JACC CardioOncol"},{"issue":"1","key":"4951_CR41","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jaccao.2020.02.006","volume":"2","author":"KJ Waddell","year":"2020","unstructured":"Waddell\u00a0KJ, Shah\u00a0PD, Adusumalli\u00a0S, Patel\u00a0MS (2020) Using behavioral economics and technology to improve outcomes in\u00a0cardio-oncology. JACC CardioOncol 2(1):84\u201396","journal-title":"JACC CardioOncol"}],"container-title":["Herz"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-020-04951-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00059-020-04951-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-020-04951-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T23:31:21Z","timestamp":1623108681000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00059-020-04951-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,8]]},"references-count":41,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["4951"],"URL":"https:\/\/doi.org\/10.1007\/s00059-020-04951-x","relation":{},"ISSN":["0340-9937","1615-6692"],"issn-type":[{"value":"0340-9937","type":"print"},{"value":"1615-6692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,8]]},"assertion":[{"value":"8 June 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical guidelines"}},{"value":"L.\u00a0Michel, D.\u00a0Schadendorf and T.\u00a0Rassaf declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"For this article no studies with human participants or animals were performed by any of the authors. All studies performed were in accordance with the ethical standards indicated in each case.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}